Navigation Links
Jazz Pharmaceuticals Receives FDA Complete Response Letter Regarding JZP-6 for Treatment of Fibromyalgia
Date:10/11/2010

PALO ALTO, Calif., Oct. 11 /PRNewswire-FirstCall/ -- Jazz Pharmaceuticals, Inc. (Nasdaq: JAZZ) announced today that the U.S. Food and Drug Administration (FDA) has sent the company a complete response letter (CRL) regarding the company's New Drug Application (NDA) for JZP-6 (sodium oxybate) for the treatment of fibromyalgia.  The CRL states that the FDA cannot approve the NDA in its present form.  In the letter, the FDA discusses a number of topics, including the need for additional clinical studies, the appropriate patient population, methods for ensuring safe use, and the proposed REMS, concentration and trade name for the product.

"We have requested a meeting with FDA in order to discuss and clarify the contents of the CRL and will then evaluate our next steps for JZP-6," said Bruce Cozadd, chairman and chief executive officer of Jazz Pharmaceuticals.  "We continue to believe there is a significant unmet medical need among fibromyalgia patients that could be met by JZP-6 if it were approved by FDA."

Conference Call Information

Jazz Pharmaceuticals will host an investor conference call and live audio webcast today (October 11) at 8:30 AM Eastern Time/ 5:30 AM Pacific Time to discuss this release and respond to investor questions.  The live webcast may be accessed from the Investors section of the Jazz Pharmaceuticals website at www.jazzpharmaceuticals.com. Please connect to the website prior to the start of the conference call to ensure adequate time for any software downloads that may be necessary.

Investors may participate in the conference call by dialing 866-700-6067 in the U.S., or 617-213-8834 outside the U.S., and entering passcode 43104766.

An archived version of the webcast will be available for at least one week on the investors section of the Jazz Pharmaceuti
'/>"/>

SOURCE Jazz Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Auxilium Pharmaceuticals, Inc. Announces Initiation of XIAFLEX® Phase III Studies for Peyronies Disease
2. Valeant Pharmaceuticals Announces That Alexza Pharmaceuticals Has Received a Complete Response Letter for AZ-004 (Staccato® Loxapine) Inhalation Aerosol NDA
3. Alexza Pharmaceuticals Receives Complete Response Letter for AZ-004 (Staccato® Loxapine) NDA
4. Bexion Pharmaceuticals Continues to Gain Support from National Cancer Institute (NCI)
5. Onyx Pharmaceuticals Provides Status Update on Carfilzomib
6. Onyx Pharmaceuticals Announces Teleconference to Provide Status Update on Carfilzomib
7. Star Scientific Comments on Roskamp Institutes Plans to Conduct Human Alzheimers Clinical Trials Using a Compound (RCP-006) Developed by Rock Creek Pharmaceuticals, Inc.
8. VentiRx Pharmaceuticals Reports Positive Clinical Data for VTX-1463 in Allergic Rhinitis
9. Regeneron Pharmaceuticals, Inc. Announces The Sale of 4,500,000 Shares of Common Stock
10. Lotus Pharmaceuticals Retains Sichenzia Ross Friedman Ference LLP as General Legal Counsel
11. ISTA Pharmaceuticals Reports Positive Preliminary Results from its Phase 1/2 Clinical Study of Bepotastine Besilate Nasal Spray for the Treatment of Symptoms Associated with Seasonal Allergic Rhinitis
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/30/2014)... , Sept. 30, 2014 This ... for molecular imaging informatics solutions including nuclear imaging ... and comparison. The study assesses the size of ... 2010 and 2013, and projects future growth based ... as the dynamics taking place in the broader ...
(Date:9/30/2014)... -- Decision Resources Group finds that the markets for peripheral ... Russia , India ... see robust expansion as these economies expand and as ... revenues will be somewhat impeded by poor distribution of ... and demand for low-cost products, the market will ultimately ...
(Date:9/30/2014)... Sciences, Inc. (NASDAQ: ALIM ) (Alimera), a ... commercialization of prescription ophthalmic pharmaceuticals, announced today that it ... Growth Capital, Inc. (NYSE: HTGC ) (Hercules). ... the Loan and Security Agreement that Alimera,s subsidiary in ... Limited, entered into with Hercules in April of this ...
Breaking Medicine Technology:Analysis of the US Molecular Imaging Informatics Market 2Analysis of the US Molecular Imaging Informatics Market 3Brazilian, Russian, Indian and Chinese Markets for Peripheral Vascular Devices Will See Strong Expansion Through 2023 2Brazilian, Russian, Indian and Chinese Markets for Peripheral Vascular Devices Will See Strong Expansion Through 2023 3Alimera Sciences Receives $25 Million Advance from Hercules Technology Growth Capital 2
... and LOS ANGELES , May 10 ... "Company" or,"China Yongxin"), one of the leading health products company ... 2010 , the Company,s subsidiary, Changchun,Yongxin Dirui Medical Co. Inc. ... for Jilin province of China . According,to ...
... May 10 /PRNewswire-Asia/ -- On April 11, ... with Beijing Un-Assegai Technical &,Trade Co. Ltd. (hereinafter referred to ... China , as claimant and U.S. Abbott,Laboratories (Abbott U.S.; NYSE: ... the,China International Economic and Trade Arbitration Commission (CIETAC), which,has recently ...
Cached Medicine Technology:China Yongxin Pharmaceuticals is Selected as one of the Qualified Pharmaceutical Distributors for Jilin Province 2China Yongxin Pharmaceuticals is Selected as one of the Qualified Pharmaceutical Distributors for Jilin Province 3Assegai Wins Big Settlement Against ABBOTT's Subsidiary 2
(Date:10/1/2014)... Chino Hills, CA (PRWEB) October 01, 2014 ... the internationally-franchised Fit Body Boot Camp fitness boot camps, ... selling personal training , with sold out business ... a stint as marketing consultant to a recent Spike ... looming, Keuilian says that now is the time for ...
(Date:10/1/2014)... FARMINGTON, Conn. (PRWEB) October 01, 2014 ... its company, including a redefined mission and visual ... the power of partnering with them to create ... more agile brand that focuses on empowering customers ... benefits communications. , The crown jewel of the ...
(Date:10/1/2014)... October 01, 2014 Innovations announces the ... to broadcast on Monday, October 20, 2014 at 7:30 ... Innovations will go behind the scenes to learn about ... segment will explore the practical help and information Break ... teaches the warning signs of abuse, how to navigate ...
(Date:10/1/2014)... On Sept. 9, Chapín Coffee was ... Martha Stewart American Made Awards (MSAMAs), an annual competition ... in the fields of crafts, design, food and style. ... finalist in the MSAMAs, which celebrates entrepreneurs and artisans ... local communities and changing the way we shop, work ...
(Date:10/1/2014)... October 01, 2014 Dr. Saj Jivraj, ... and prosthodontists, is traveling to Chennai, India, tomorrow to ... Oct. 2 and 3. , Dr. Jivraj is founder ... and Oxnard, Calif., and one of the world’s foremost ... and replacement. He is speaking to the Indian Society ...
Breaking Medicine News(10 mins):Health News:Bedros Keuilian Shares Tips on Selling Personal Training for the Holidays 2Health News:Bedros Keuilian Shares Tips on Selling Personal Training for the Holidays 3Health News:Farmington Company Launches Rebrand and New Positioning 2Health News:Innovations to Explore Breakthroughs in Health and Wellness in Upcoming Episode Airing Monday, October 20, 2014 via Discovery Channel 2Health News:Chicago Coffee Start-up Makes a Big Impact, Earns National Recognition 2Health News:One of Woodland Hills’ Top Cosmetic Dentists Speaking to Indian Society of Oral Implantologists Tomorrow 2Health News:One of Woodland Hills’ Top Cosmetic Dentists Speaking to Indian Society of Oral Implantologists Tomorrow 3Health News:One of Woodland Hills’ Top Cosmetic Dentists Speaking to Indian Society of Oral Implantologists Tomorrow 4Health News:One of Woodland Hills’ Top Cosmetic Dentists Speaking to Indian Society of Oral Implantologists Tomorrow 5
... Association of Retired Xerox Employees, Inc. (ARXE) has retained ... R. Pfalzgraf, Jr., Esq., and Danielle Shainbrown, Esq.) and ... action against Xerox Corporation, in an effort to maintain ... retirees. , Beginning in 2010, nearly 25 percent of ...
... Sept. 30 Connectyx Technologies Holding Group Inc. (Pink Sheets: ... York, NY as its independent registered public accountant for the ... be provided include auditing and preparation for filing Form 10 ... for Connectyx in order to become a Fully Reporting Company ...
... Orexigen® Therapeutics, Inc. (Nasdaq: OREX ) today announced ... SR/zonisamide SR), the Company,s second late stage investigational combination ... efficacy endpoint by demonstrating statistically significantly greater weight loss ... The Company plans to meet with the U.S. ...
... Halloween just around the corner, health-conscious adults and trick-or-treaters ... other snacks that are starting to hit store shelves. ... alternative treat that won,t derail their healthy lifestyles need ... Milk®. , Tiger,s Milk has delivered essential proteins, ...
... , CLAREMONT, Calif., Sept. 30 ... Program (PBPM), scheduled to begin in January 2010, for those ... interested in enhancing their skills before applying to medical school. ... a career as a medical professional," says Sheldon M. Schuster, ...
... BEIJING, Sept. 30 /PRNewswire-Asia/ -- Sinovac Biotech Ltd. (NYSE: ... China, announced today that,Sinovac has received its second purchase ... Industry and Information Technology of the People,s,Republic of China ... is required to produce an additional 3 million doses ...
Cached Medicine News:Health News:Association of Retired Xerox Employees Initiate Legal Proceedings Against Xerox Corporation 2Health News:Connectyx Technologies Retained the Marcum Group in New York as its Independent Registered Public Accountant for the Purpose of Becoming a Fully Reporting Company 2Health News:Orexigen(R) Therapeutics Phase 2b Trial for Empatic(TM) Meets Primary Efficacy Endpoint Demonstrating Significantly Greater Weight Loss Versus Comparators in Obese Patients 2Health News:Orexigen(R) Therapeutics Phase 2b Trial for Empatic(TM) Meets Primary Efficacy Endpoint Demonstrating Significantly Greater Weight Loss Versus Comparators in Obese Patients 3Health News:Orexigen(R) Therapeutics Phase 2b Trial for Empatic(TM) Meets Primary Efficacy Endpoint Demonstrating Significantly Greater Weight Loss Versus Comparators in Obese Patients 4Health News:Orexigen(R) Therapeutics Phase 2b Trial for Empatic(TM) Meets Primary Efficacy Endpoint Demonstrating Significantly Greater Weight Loss Versus Comparators in Obese Patients 5Health News:Orexigen(R) Therapeutics Phase 2b Trial for Empatic(TM) Meets Primary Efficacy Endpoint Demonstrating Significantly Greater Weight Loss Versus Comparators in Obese Patients 6Health News:Have a Healthier Halloween with Tiger's Milk(R) 2Health News:KGI Establishes Post Baccalaureate Premedical Program 2Health News:Sinovac Obtains Second Order of H1N1 Vaccine from Chinese Central Government 2Health News:Sinovac Obtains Second Order of H1N1 Vaccine from Chinese Central Government 3
... Philip's EASITrak 12 gives you the detailed ... treatment decisions for your patients with palpitations, ... with the EASI Lead System, this transtelephonic ... to capture a derived 12-lead ECG. Comfortable ...
... Viewer Phonocardiogram (PCG). The ZAC-Viewer is ... to record, condition, display and print heart ... The product acquires and displays the recorded ... sites, and allows user-selectable filtering of each ...
... with the challenge of,controlling costs while ... patient data,management is critical. INFINITY modular,patient ... important clinical information,wherever you are in ... concept,makes your job easier. You can ...
... system is a combination of a Siemens SOMATOM ... AXIOM Multistar angiography unit. Both systems use the ... between floating DSA position and fixed CT position. ... the park position. When it is nesessary to ...
Medicine Products: